Home>Topics>Stocks>Vertex Pharmaceuticals

Vertex Pharmaceuticals VRTX

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. Headlines
    1. 10 High-Conviction Purchases by Our Ultimate Stock Pickers

      Headlines

      Tue, 21 May 2013

      04 Medium 6,901 2 Cigna CI 2 None 67.90 1.19 High 19,529 2 St Jude STJ 3 Wide 47.00 0.96 Medium 13,369 2 Vertex VRTX 3 None 79.49 0.89 High 17,961 2 Pioneer PXD 1 Narrow 142.25 1.50 Medium 19,943 1 Devon DVN 5 Narrow 58.79 0.59

    2. Biotech names are weak today on the back of several ASCO data presentation releases: [[REGN]] -2.3%, [[ALXN]] -4.2%, [[ VRTX ]] -2.3%, [[CELG]] -4.5%, [[ARRY]] -2.2%, [[AMGN]] -1.4%.

      Headlines

      Thu, 16 May 2013

      Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3% , ALXN -4.2% , VRTX -2.3% , CELG -4.5% , ARRY -2.2% , AMGN -1.4% . 1 comment!

    3. This Stock Deserved Its Sudden Upswing

      Headlines

      Mon, 13 May 2013

      By Northwest Trader : Cystic Fibrosis (CF) is caused by a defective gene that causes the body to produce thick, sticky mucus that clogs the lungs, promotes life threatening infections, causes diabetes, infertility, and hinders normal breakdown of nutrition and nutritional absorption. It is an evil

    4. Vertex Debt Conversion Is Not Bad For Shareholders

      Headlines

      Thu, 9 May 2013

      By John Fifield: As of late there has been a lot of chatter about how Vertex's ( VRTX ) stated intention to retire some debt into equity is bad for current shareholders. The chatter has been relentless by Vertex

    5. Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential

      Headlines

      Fri, 3 May 2013

      By Life Sciences Report : In January 2013, The Life Sciences Report debuted its biotech Watchlist, which outlined ideas for investors keyed to catalysts in the drug development process that typically move biotechnology stocks. All stocks are affected by catalysts, but nowhere do they provide more

    6. Vertex Pharmaceuticals Beats Analyst Expectations, Yet Insiders Continue To Sell More Shares

      Headlines

      Fri, 3 May 2013

      By Edward Vranic : The stock price of Vertex Pharmaceuticals ( VRTX ) spiked up 3% in early Wednesday trading after the ..... revenue and net earnings. However, by the end of the day VRTX gave up all but one penny of its gains to close at

    7. Why BioMarin, Catalyst Pharmaceutical Partners And Vertex Are Expected To Outperform

      Headlines

      Wed, 1 May 2013

      By Tom Welch: Recently, shares of Catalyst Pharmaceutical Partners ( CPRX ) and Vertex Pharmaceuticals ( VRTX ) spiked dramatically upward, drawing the attention of many traders and investors. BioMarin ( BMRN ) has not been as dramatic

    8. Vertex Pharmaceuticals Incorporated Management Discusses Q1 2013 Results - Earnings Call Transcript

      Headlines

      Tue, 30 Apr 2013

      Vertex Pharmaceuticals Incorporated ( VRTX ) Q1 2013 Earnings Call April 30, 2013 5:00 pm ET Executives ..... http://seekingalpha.com/article/1387481- vertex - pharmaceuticals -incorporated-management-discusses-q1-2013-results-earnings-call-transcript

    9. UPDATE 3-Vertex posts loss, raises cystic fibrosis sales view

      Headlines

      Tue, 30 Apr 2013

      April 30 (Reuters) - Vertex Pharmaceuticals Inc on Tuesday increased by $20 million the 2013 forecast for sales of its cystic fibrosis drug Kalydeco, and said it anticipates seeking approval in 2014 of a CF combination therapy that has become a focus for investors.

    10. More on Vertex Pharmaceuticals ( VRTX ): Q1 beats on both EPS and revenue, but net profit swung to a loss on a 25% drop in total sales as fewer patients initiated treatment - leading to a 42% drop in ...

      Headlines

      Tue, 30 Apr 2013

      More on Vertex Pharmaceuticals ( VRTX ): Q1 beats on both EPS and revenue, but net profit swung to a loss on a 25% drop in total sales as fewer patients initiated

    « Prev12345Next »
    Content Partners